Advances in detection technologies reveal new blood-based biomarkers for Alzheimer's disease, suggesting less invasive diagnostics.
Current diagnostic approaches for Alzheimer's disease (AD), including neuroimaging and cerebrospinal fluid (CSF) analysis, are limited by their invasiveness, high cost, and restricted accessibility. In contrast, ultrasensitive blood-based assays overcome...
No takes yet. Share an insight, caveat, or question.
Mou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: